---
title: 'Can Integer Holdings (ITGR) Stock Double in 3 Years? A Simple 3-Anchor Valuation Breakdown'
abstract: 'This article evaluates whether Integer Holdings (ITGR) can realistically deliver 2× returns over the next three years using three non-overlapping valuation anchors: EV/EBITDA, EV/Sales, and Free Cash Flow yield (EV/FCF). It breaks each outcome into fundamentals growth, valuation rerating/derating, and per-share effects (debt and dilution) to estimate a grounded 3-year price multiplier.'
date: 'February 10, 2026'
datetime: '2026-02-10'
category: { title: 'Equity Research - Valuation', slug: 'equity-research-valuation' }
slug: '2026-02-10-itgr-2x-in-3-years-valuation'
seoKeywords:
  [
    'ITGR',
    'Integer Holdings',
    'ITGR stock',
    'Integer Holdings valuation',
    'medical device outsourcing',
    'medical device manufacturer',
    'EV/EBITDA',
    'EV/Sales',
    'free cash flow yield',
    'EV/FCF',
    'can it double',
    '2x in 3 years',
    'stock price multiplier',
    'medical OEM supplier',
    'debt paydown',
    'dilution risk',
  ]
---

## Overall view

Medical device outsourcing should keep growing over the next few years because large OEMs keep pushing more design-and-manufacturing work to specialized partners, and many of Integer’s programs are “sticky” once designed into regulated device platforms. The stock does not look like a hype trade today; the bigger story is that the share price has fallen meaningfully versus where it traded around FY2024, which usually means the market is worried about the durability of growth, margins, or cash conversion. Integer has a strong business model (high switching costs, deep engineering integration), but 2× in three years is still a high bar because the equity upside must overcome meaningful net debt and because free cash flow has been uneven. Revenue $1.07B → $1.72B (FY20–FY24); EBIT margin ~9.7% → ~13%; net debt roughly ~$0.74B → ~$1.06B. The single biggest reason 2× is hard is that you likely need both continued double-digit operating compounding and a valuation rerating back toward prior premium levels, while also improving per-share economics through deleveraging (or at least avoiding dilution).

---

## PRIMARY framework / anchor: EV/EBITDA

### A) Anchor selection + baseline

EV/EBITDA is the cleanest “what drives the stock” anchor for Integer because it is a scaled manufacturing-and-engineering platform where the market usually prices the business on operating profit power (not just sales) while looking through capital structure. Using the inputs provided and treating FY2024 net debt (~$1.06B) and shares (~33.6M) as still roughly representative (because no newer balance sheet was provided), today’s price of $86.28 implies market cap of about ~$2.9B and EV of about ~$4.0B. Against FY2024 EBITDA of ~$333M, that is roughly ~12× EV/EBITDA. That is below the company’s own recent history where EV/EBITDA sat in the mid-teens (roughly ~15–19× across FY2020–FY2024 in the provided ratio history), which suggests the market has already “derated” the stock.

### B) 2× hurdle vs likely path

A true 2× in 3 years requires about ~26% per year. In plain terms, that usually means either (a) per-share operating earnings/cash flows compounding at something like the mid-to-high teens annually plus some rerating, or (b) more modest fundamentals growth but a very strong valuation rerating, or (c) a combination of both plus meaningful debt paydown or buybacks.

Under EV/EBITDA, 2× typically needs EBITDA to grow to something like ~1.5×–~1.7× in three years (think low-to-mid teens EBITDA growth per year), and/or the EV/EBITDA multiple to move up meaningfully (for example from ~12× back toward ~15×–~17×). Because Integer carries meaningful net debt, there is also a “per-share boost” available if net debt comes down; but that boost is only meaningful if free cash flow supports real deleveraging without heavy dilution.

Based on the company’s FY2020–FY2024 history, a realistic “most likely” operating path is revenue growing in the high single digits to low double digits (the company has shown ~9%–~17% revenue growth in the last few years, but it is prudent to fade that toward ~7%–~10% as the base), and margins improving modestly rather than dramatically (EBIT margin has already moved from ~10% toward ~13%, and further improvement is possible but tends to be incremental in contract manufacturing). EBITDA growth in that world is often around ~8%–~12% per year, which is roughly ~1.26×–~1.40× over three years. On leverage, the debt load is manageable but not trivial; in a normal case you might see modest net debt reduction rather than a dramatic deleveraging, and share count could drift up slightly if acquisitions or stock comp outweigh buybacks.

Comparing required vs likely outcomes, the gap is that 2× wants both a high EBITDA compounding rate and a rerating, while the “most likely” path is solid compounding but not enough on its own. Net: fundamentals ~1.26× to ~1.40×; valuation ~1.05× to ~1.25×; per-share ~1.05× to ~1.15×; total ~1.40× to ~2.05×. 2× needs a combination of above-trend EBITDA growth, a rerating back toward the mid-teens EV/EBITDA zone, and real net debt reduction without meaningful dilution.

### C) Outcome under this anchor

A grounded base case is EBITDA up about ~10% per year, which is about ~1.33× over three years, coming from ~8% sales growth plus a small margin lift from better mix, utilization, and execution. If the market regains confidence and moves the multiple from roughly ~12× today back to about ~13.5× (still below the company’s recent mid-teens history), that is about ~1.1×–~1.15× of valuation uplift. For per-share effects, if net debt declines by roughly ~$150M–~$200M over three years (not aggressive given recent free cash flow levels, but achievable if cash conversion stays decent) while shares drift up only slightly (~0%–~2% total), the equity value can get an extra lift because reducing debt increases the portion of enterprise value that belongs to equity holders.

Putting that together yields a base-case 3-year price multiplier of about ~1.7×, with a defensible range of ~1.4× to ~2.1× under this anchor. Using the current price of $86.28, that translates to an implied 3-year price of about ~$149 in the base case, with a plausible range of roughly ~$121 to ~$179. The high end requires Integer to both execute well enough to keep EBITDA compounding near the top of its realistic band and to convince the market to pay a meaningfully higher multiple again, while also deleveraging rather than issuing stock.

---

## CROSS-CHECK framework / anchor #1: EV/Sales

### A) Anchor selection + baseline

EV/Sales is a useful cross-check because it focuses on the durability of top-line program growth and the “quality premium” investors will pay for regulated, sticky medical manufacturing revenue streams, without leaning on near-term margin assumptions. Using the same “no-newer-data-provided” snapshot implied by the current price, EV is about ~$4.0B and FY2024 revenue is ~$1.72B, so EV/Sales is about ~2.3× today. In the provided history, EV/Sales has been closer to ~2.45×–~3.25× across FY2020–FY2024, so today’s multiple again looks like a discount to its own recent norms.

### B) 2× hurdle vs likely path

The 2× hurdle still means ~26% per year, but under EV/Sales you can think of it as “sales growth times multiple change, adjusted for debt and dilution.” If sales compound at high single digits, that alone will not double the stock; you would also need the market to pay a notably higher EV/Sales multiple and/or you need a meaningful per-share boost from deleveraging.

For ~2× to happen cleanly under EV/Sales, a plausible recipe might look like sales up ~1.3×–~1.4× over three years (high single digits to low double digits annually), EV/Sales moving from ~2.3× toward ~2.9×–~3.0× (back near the upper half of its own recent range), and net debt coming down enough that more of the enterprise value increase accrues to equity. If any one of those legs is missing (especially rerating or deleveraging), it becomes hard to get to 2×.

Based on history and business mechanics, a more likely path is sales up around ~1.23×–~1.33× over three years (roughly ~7%–~10% annual growth) because the end markets are steady but not explosive, and because outsourcing growth tends to be persistent but not “hypergrowth.” On valuation, moving from ~2.3× to something like ~2.6× is reasonable if execution stays strong and sentiment normalizes, but jumping all the way back to the top of the prior band generally requires unusually strong growth visibility or a major margin/return uplift (which EV/Sales investors often infer even if it is not explicitly modeled). Net debt likely helps, but only modestly unless free cash flow meaningfully accelerates.

Required vs likely gap: the base case can get you most of the way there, but it still usually falls short of a clean 2× unless the multiple climbs sharply and/or debt drops faster than the “normal” pace. Net: fundamentals ~1.23× to ~1.33×; valuation ~1.05× to ~1.30×; per-share ~1.03× to ~1.15×; total ~1.30× to ~2.00×. 2× needs sales to hold near the top of the band and EV/Sales to re-rate close to ~3× while deleveraging meaningfully.

### C) Outcome under this anchor

A grounded base case is sales up ~8% per year, or about ~1.26× over three years, reflecting steady procedure growth and continued outsourcing penetration plus some share gains in complex categories. If EV/Sales rises from ~2.3× to ~2.6× (a moderate normalization that is still below the company’s recent “premium” levels), that is about ~1.1×–~1.15× of valuation uplift. On per-share effects, modest net debt reduction helps equity holders because it reduces the “debt claim” against enterprise value, while slight dilution is a mild headwind.

That combination points to a base-case 3-year multiplier of about ~1.6×, with a defensible range of ~1.3× to ~2.0× under this lens. Using $86.28 today, the implied 3-year price is about ~$139 in the base case, with a plausible range of roughly ~$113 to ~$173. This anchor tends to be generous on the high end only if the market is willing to award a stronger “quality premium” again, which usually requires very consistent execution and cleaner cash conversion.

---

## CROSS-CHECK framework / anchor #2: Free cash flow yield (EV/FCF)

### A) Anchor selection + baseline

Free cash flow yield is the discipline anchor because it forces the question: “How much real cash does this business generate relative to the total enterprise value, after capex and working capital needs?” This matters for Integer because debt paydown (a major potential per-share lever) can only happen through sustained free cash flow. Using FY2024 free cash flow of about ~$100M, today’s implied EV of about ~$4.0B equates to EV/FCF around ~40× (roughly ~2.5% FCF yield), which is not obviously cheap. Because FCF has been uneven (for example, it was much higher in FY2020–FY2021 and weaker in FY2022–FY2023 before recovering in FY2024), it is reasonable to also think in “normalized” terms; if normalized FCF is closer to ~$110M, the multiple is still about ~36× (roughly ~2.8% yield). Either way, this anchor suggests the stock’s upside depends heavily on FCF expanding, not just EBITDA.

### B) 2× hurdle vs likely path

To reach 2× using a cash-flow lens, you need a big step-up in annual free cash flow and/or you need investors to accept a lower yield (a higher EV/FCF multiple). Put simply, the market needs to believe the company can sustainably convert earnings into cash, and that the cash is durable enough to deserve a premium multiple.

A 2× path under this anchor often looks like FCF rising to ~1.6×–~2.0× over three years (mid-teens to ~20% annual FCF growth), combined with a stable-to-higher EV/FCF multiple (meaning the yield stays low). Debt reduction can also help the equity outcome, but only if FCF is strong enough to pay it down without offsetting dilution or reinvestment spikes.

History suggests a more conservative stance: capex has been meaningful recently and working capital has sometimes absorbed cash, which is why FCF margins have swung. If revenue keeps growing but the business also keeps investing (and if working capital remains a use of cash during growth spurts), FCF may grow, but it may not explode. A realistic band might be FCF growing around ~8%–~15% per year, or about ~1.26×–~1.52× over three years, with the “extra” upside coming only if working capital normalizes and capex intensity does not rise faster than sales. On valuation, if cash flow becomes more consistent, the market might accept a similar or slightly better yield, but it is hard to assume a big premium rerating on EV/FCF when the current implied yield is already not high.

The gap is straightforward: 2× needs a much cleaner cash step-up than the recent pattern proves, plus no meaningful yield headwind. Net: fundamentals ~1.26× to ~1.55×; valuation ~0.90× to ~1.10×; per-share ~1.03× to ~1.12×; total ~1.20× to ~1.90×. 2× needs unusually strong FCF scaling (and likely working-capital release) while the market continues to pay a premium cash multiple.

### C) Outcome under this anchor

A grounded base case assumes normalized free cash flow today is around ~$110M and grows about ~12% per year, which is roughly ~1.40× over three years, driven by steady growth and modest improvement in cash conversion as the business scales. If the valuation ends up roughly flat-to-slightly less generous on EV/FCF (for example moving from about ~36× to about ~34× as the market demands a bit more yield), that is a small valuation headwind of roughly ~0.95×. If net debt comes down modestly (helping equity holders) while share count drifts slightly higher, the net per-share effect can still be a mild tailwind.

That math points to a base-case 3-year multiplier of about ~1.5×, with a defensible range of ~1.2× to ~1.9× under this cash lens. Using $86.28 today, the implied 3-year price is about ~$127 in the base case, with a plausible range of roughly ~$104 to ~$164. The message from this anchor is that “cash, not just EBITDA,” is what most likely decides whether the stock can rerate and delever enough to justify a 2× outcome.

---

## Final conclusion

Triangulating the three anchors, Integer looks like a solid compounder, but a clean 2× in three years requires multiple things to go right at once: sustained strong operating growth, valuation normalization back toward prior premium bands, and enough free cash flow to reduce net debt without offsetting dilution. The most likely 3-year multiplier is about ~1.6×, with a tighter realistic range of ~1.45× to ~1.80×, which roughly corresponds to fundamentals contributing about ~1.30×–~1.40×, valuation contributing about ~1.05×–~1.15×, and per-share effects contributing about ~1.05×–~1.10×. The 2× verdict is Borderline: it is achievable, but it likely requires above-trend EBITDA/FCF scaling plus a rerating back into the mid-teens EV/EBITDA neighborhood while net debt declines meaningfully. The single swing factor that would most likely change the answer is sustained free cash flow improvement (cleaner working-capital behavior and strong conversion), because that both supports deleveraging and makes a premium multiple easier to justify. With ITGR at $86.28 (as of February 10, 2026), the midpoint implied 3-year price is about ~$138, with an implied 3-year price range of roughly ~$125 to ~$155; in plain English, “~1.6× maps to about $138, and ~1.45×–~1.80× maps to about $125–$155.”
